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Purpose. To analyze in mild Alzheimer’s disease (MAD) patients, GDS-4 (Reisberg Scale), whether or not some psychophysical
tests (PTs) support OCT macular findings in the same group of MAD patients reported previously.Methods. Twenty-three MAD
patients and 28 age-matched control subjects with mean Mini Mental State Examination of 23.3 and 28.2, respectively, with no
ocular disease or systemic disorders affecting vision were included. Best-corrected visual acuity (VA), contrast sensitivity (CS) (3,
6, 12, and 18 cpds), color perception (CP), and perception digital test (PDT) were tested in one eye of each patient. Results. In
comparison with the controls, MAD patients presented (i) a significant decrease in VA, PDT, and CS for all spatial frequencies
analyzed, especially the higher ones, and (ii) a significant increase in unspecific errors on the blue axis (𝑃 < 0.05 in all instances). In
MADpatients, a wide aROC curve was plotted in all PTs.Conclusions. InMAD, CS, VA, and the tritan axis in CPwere impaired.The
PTs with the greatest predictive value are the higher spatial frequencies in CS and tritan unspecific errors in CP. PT abnormalities
are consistent with the structural findings reported in the same MAD patients using OCT.
1. Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder of
the central nervous system characterized by cortical atrophy
most pronounced in the medial temporal and posterior tem-
poroparietal regions [1]. Disturbances of short-termmemory,
judgment, and emotion are characteristic of the disease.
As an extension of the central nervous system, the
retina displays similarities to the brain in terms of anatomy,
functionality, response to insult, and immunology [2–4].
Furthermore, the retina presents manifestations of major
neurodegenerative diseases, and it has been argued that
several ocular diseases should be viewed as forms of neu-
rodegenerative disorders [2].This unique propertymakes the
retina a valuable tool for in vivo visualization and study of
retinal changes.
The first histopathologic evidence of postmortem retinal
changes fromAD patients was reported by Hinton et al., who
found a significant axonal degeneration in the optic head
nerve [5]. Further studies have demonstrated that a decrease
in retinal ganglion cell numbers was associated with an array
of intracellular injuries [6]. The analysis on the distribution
of neuronal loss in the retina by Blanks et al. showed that the
most pronounced areas of cell loss in the ganglion cell layer
(GCL) were the superior and inferior retinal quadrants [7]
and there was an extensive loss of RGC in the temporal foveal
region [8]. These findings have been corroborated using the
Optical Coherence Tomography (OCT), demonstrating the
decrease of the RNFL and the macular thickness [9–16], even
in early stages of mild cognitive impairment [12, 17–19].
Currently it is thought that RGC loss in AD might result
from amyloid pathology in the retina. Both amyloid-beta
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plaques and oligomers have been reported in the human
retina [4, 20–25]. Therefore, amyloid accumulation in the
retina of patients with AD may result in the degeneration of
RGCs in parallel with amyloid-beta-related neurodegenera-
tion in the brain [25]. However, retinal findings in AD could
be also due to retrograde degeneration of RGCs secondary
to AD pathology in the central visual pathways, given that
ADpatients showdegeneration of the primary and secondary
visual cortex [26].
In addition to the anatomical findings inADpatients, this
disease can exert an impact on most aspects of visual pro-
cessing, such as visual field abnormalities [27–29], color per-
ception deficits [30–32], pattern electroretinogram changes
[11, 33, 34], and reduced contrast sensitivity (CS) [35–38].
The M visual pathway appears to be particularly vul-
nerable to degeneration in AD [26]. Thus, degeneration of
RGCs and/or visual pathways in the brain may underlie the
functional deficits in CS seen in patients with AD [29]. CS
function in humans diminishes with changes in the retina,
the optic nerve, and lesions of the occipital, temporal, and/or
parietal cortices [39].
Psychophysical investigations of CS in AD patients have
rendered results consistent with the neuropathological evi-
dence. However, studies of CS in patients with AD have
yielded variable results. Some studies have reported no AD-
related deficits in spatial CS [40, 41], while others have found
deficits at all spatial frequencies tested [42].
OCTmacular studies in ADby our group and others have
recently reported that mild AD (MAD) patients with a high
mean score (23.3±3.1) on theMiniMental State Examination
(MMSE) had significantly reduced macular nerve fiber layer
thickness with or without significant peripapillary involve-
ment [9, 43, 44]. In the present study, to analyze whether
these anatomical features coexist with alterations in the
visual functional state in MAD patients, we include the same
patients from the previous work [9]. To examine the visual
pathway in this homogeneous group (in terms of disease
stage) of MAD, we performed different psychophysical tests,
specifically visual acuity (VA), CS, color perception, and
perception digital test (PDT). The results are compared with
those of an age-matched control group in order to (i) improve
our understanding on how the visual pathway works inMAD
and (ii) determine whether or not these tests support early
macular findings on OCT in MAD.
2. Materials and Methods
2.1. Subjects. To select patients, we reviewed the Database
of the Memory Unit of the Hospital Cl´ınico San Carlos
in Madrid (Spain), consisting of a total of 2635 patients.
First, we excluded the patients with a Global Deterioration
Scale (GDS) over 4 [45] and then those with a mood or
psychiatric disorder. Next, we took into account 87 patients
withMAD.These patients, according to theNational Institute
of Neurological and Communicative Disorders and Stroke-
Alzheimer’s Disease and Related Disorders Association and
the Diagnostic and Statistical Manual of Mental Disorders
IV, had mild cognitive impairment according to the Clinical
Dementia Rating Scale. Then ophthalmic medical records
of these patients were reviewed, excluding those patients
who were previously diagnosed with an ophthalmic condi-
tion. After this analysis, 29 patients with AD had all the
requirements to participate in the study (GDS over 4 and
freedom of ocular disease and systemic disorders affecting
vision in their medical record). Of the 29 MAD patients
and 37 age-matched control subjects selected (normalMMSE
scores), 6 MAD patients and 9 age-matched control subjects
were subsequently excluded due to posterior pole pathol-
ogy including macular degeneration, drusen, suspicion of
glaucoma, glaucoma, epiretinal membrane, or cataract that
prevented ocular examination. Because of this selection, 23
patients withMADand 28 age-matched control subjects were
considered for the study. Informed consent was obtained
from both groups. The research followed the tenets of the
Declaration ofHelsinki, and the protocol was approved by the
local ethics committee.
2.2. Methods. The clinical evaluation of our MAD included
a review of the medical records, a caregiver interview,
physical and neurological examinations, a psychometric test,
neuroimaging techniques, and routine laboratory testing for
dementia.
For the ophthalmological part of the study only one eye of
each patient was analyzed. All participants met the following
inclusion criteria: being free of ocular disease, AREDS Clini-
cal Lens Standards <2, retinal drusen and systemic disorders
affecting vision, having a best-correctedVAof 20/40, having a
±5 spherocylindrical refractive error, and having intraocular
pressure of less than 20mmHg. For screening, all ADpatients
and control subjects underwent a complete ophthalmologic
examination, including assessment of VA, refraction, ante-
rior segment biomicroscopy, applanation tonometry (Perkins
MKII tonometer, Haag Streit, RelianceMedical, Switzerland),
CS test CSV-1000E (VectorVision, Greenville, OH, USA),
Roth 28-hue color test (Luneau, Paris, France), PDT [46],
and dilated fundus examination. In the dilated fundus exam-
ination, no differences were found between MAD patients
and age-matched control subjects. These tests were selected
considering that in this developmental stage of the disease
the results were not influenced by the patient’s cognitive
impairment.
2.3. Visual Acuity. Monocular best-corrected distant VA was
determined using a standard clinical Snellen eye chart. The
correction was based on the subjective refraction of the
subject. The patients started to read each row from the top
of the Snellen eye chart and proceeded toward the bottom.
This was ended when the hit rate was less than five of
eight (an approximation to 56.25%, the steepest point of the
psychometric acuity function).
2.4. Contrast Sensitivity Function. TheCS test was performed
under the same conditions for all the patients and with
the CSV-1000E system (VectorVision, Greenville, OH, USA)
and in the presence of best-corrected VA for far vision. The
CSV-1000E test provides a fluorescent luminance source that
retroilluminates a translucent chart and is able to monitor
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and autocalibrate the light level to 85 cd/m2. The CSV-
1000E was performed at 98.5 inches as recommended by the
manufacturer. The nonselected eye was occluded for each
measurement. The translucent chart presents four spatial
frequencies: 3, 6, 12, and 18 cyc/deg. Each spatial frequency
was presented on a separate row of the test. Each row
presented 17 circular patches 1.5 inches in diameter. The first
patch in the row had a very high contrast grating (sample
patch) on the far-left side of the row. The remaining 16
patches appeared in 8 columns presented across the row. In
each column, one patch presented a grating while the other
patch remained blank. The patches that presented gratings
decreased in contrast from left to right across the row. The
patient was directed to observe the first sample patch and to
look for the grating pattern in each column. While reading
across the row, the patient indicated whether the grating
appeared in the top patch or the bottompatch of each column.
If the grating was not visible in either patch, the patient was
to report that both were blank. The patient was encouraged
to guess whether a grating was at least partially visible as
the threshold was approached. However, the patient was
cautioned that if no gratings were visible, then the response
should be “both blank.” The contrast level of the last correct
response was recorded as the threshold.
2.5. Color Perception. To administer a color-vision test that
did not require a naming response, we usedRoth 28-hue color
test (Luneau, Paris), a quick and easy color arrangement test
first described by Roth [47]. Color perception was assessed
in the presence of best-corrected VA for near vision. The
test uses the equivalent of every third color cap from the
Farnsworth-Munsell 100 (F-M 100) as an abbreviated version.
Subjects were instructed to select the cap most similar to the
reference cap, then the cap most similar to the previously
chosen one, and so on and to place them in sequential order
until all 27 caps were arranged in a circular sequence. Test
instructions were repeated by the examiner during test when
necessary. The time to perform the test was not restricted
and the subject was allowed to make corrections. The results
were recorded on diagrams provided by the manufacturer
which depict the direction of axes corresponding to several
types of color-vision defects. Errors classified the observer
as protanomalous, deuteranomalous, or tritanomalous (red-,
green-, or blue-deficient, resp.). Following themanufacturer’s
manual [48] blue axis errors were considered when caps 43
to 64 were malpositioned. In this way, the tritan errors were
quantified.
2.6. Perception Digital Test (PDT). The PDT, developed in
2007 [46], is an easy, fast, and sensitivemethod for evaluating
disorders of visual perception in MAD patients. The aim
of the test is to assess the visual recognition of familiar
situations, masked by geometric special effects that hinder
perception. The test includes 15 sheets. Each sheet shows the
same picture at different positions in space. The pictures are
distorted by the choice of special effects: geometric effect
(tile) and effect of the frame 24/48 of MGI Photo Suite III
program. The test includes five photographs of landscapes,
six of common objects, two of people, one of an animal, and
Table 1: Demographic and clinical data of the study groups.
AD Control
𝑃 value
(𝑛 = 23) (𝑛 = 28)
Age∗ 79.3 ± 4.6 72.3 ± 5.1 0.274
Gender 0.614
Men 9 9
Female 14 19
Race Caucasian Caucasian
MMSE∗ 23.3 ± 3.1 28.2 ± 1.9 0.001††
Range (17–29) Range (25–31)
Educational level∗ 1.43 ± 0.78 1.43 ± 0.79 0.950
∗Mean value ± SD; ††𝑃 < 0.01 Mann-Whitney 𝑈 test (AD: Alzheimer’s
disease; MMSE: Mini Mental State Examination; SD: standard deviation).
one of a letter.The patient had to identify the picture that was
properly oriented in space.
2.7. Statistical Analysis. Data for the statistical analysis were
introduced and processed in SPSS 19.0 (SPSS Inc.©, Inc.,
Chicago, IL, USA). The data are reported as mean values ±
SD. The differences between MAD and control eyes were
analyzed using the Mann-Whitney test. Sensitivity at 90%
specificity and area under the receiver operator characteristic
(aROC) analysis for discriminating between healthy and
MAD patients were calculated for all the psychophysical tests
analyzed. The association between the tests and MMSE was
evaluated by Pearson’s correlation coefficient. A 𝑃 value of
<0.05 was considered statistically significant.
3. Results
Demographic and clinical data for the MAD patients and
control group are shown in Table 1.There were no statistically
significant differences in age, gender, or educational level
between the study groups. The MMSE scores in MAD
patients were significantly decreased in comparisonwith age-
matched control subjects (Table 1). All MAD patients had
MMSE values higher than 17.
3.1. Visual Acuity. The mean VA in MAD patients sig-
nificantly decreased in comparison with the age-matched
control group (Table 2; Figure 1(a)). VA showed a wide aROC
(Table 3; Figure 2(a)). A positive and statistically significant
linear association was found between VA and MMSE score
(Table 4).
3.2. Contrast Sensitivity. All analyses were conducted with
log CS values. 30.43% of the MAD patients (𝑛 = 7) were
not able to report the orientation of the 18-cpd grating at the
highest contrast level. Three of these 7 MAD patients were
also unable to detect the 12-cpd grating at any contrast value.
The analysis of CS of theMADpatients revealed a statistically
significant reduction at all spatial frequencies tested (3, 6,
12, and 18 cpds) in comparison with age-matched control
subjects (Table 2; Figure 1(b)). In addition, it was found that
the higher the spatial frequency, the greater the loss of CS
4 Journal of Ophthalmology
Table 2: Mean data and 𝑃 value of the psychophysical tests.
Test AD group Control group % difference 𝑃 value
Visual acuity (dec)∗ 0.78 ± 0.19 0.95 ± 0.06 −17.89 0.001††
Contrast sensitivity∗
3 cpds 1.39 ± 0.27 1.62 ± 0.19 −14.61 0.001††
6 cpds 1.58 ± 0.24 1.88 ± 0.22 −16.03 0.001††
12 cpds 1.12 ± 0.33 1.46 ± 0.20 −23.05 0.001††
18 cpds 0.61 ± 0.37 1.11 ± 0.27 −44.57 0.001††
Rue 28-hue∗
Number of errors 7.41 ± 4.69 5.95 ± 4.06 24.54 0.18
Tritan unspecific errors 4.35 ± 2.40 2.52 ± 2.00 72.62 0.009††
PDT (sheet)∗
Successful number of sheets 11.74 ± 2.39 13.79 ± 1.47 −14.87 0.01†
∗Mean value ± SD; †𝑃 < 0.05, ††𝑃 < 0.01Mann-Whitney 𝑈 test (AD: Alzheimer’s disease; cpds: cycles per degree; PDT: perception digital test).
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Figure 1: Mean data of the psychophysical tests. (a) Visual acuity, (b) contrast sensitivity, (c) desaturated Rue 28-hue color test, and (d)
perception digital test. Each bar represents the mean ± SD. ∗𝑃 < 0.05 versus control. ∗∗𝑃 < 0.01 versus control. Mann-Whitney 𝑈 test.
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Table 3: aROC analysis of psychophysical tests in mild Alzheimer’s
disease.
Psychophysical test aROC SD 𝑃 value
Visual Acuity 0.771 0.072 0.001††
Contrast sensitivity
3 cpds 0.755 0.072 0.002††
6 cpds 0.808 0.061 0.001††
12 cpds 0.832 0.064 0.001††
18 cpds 0.857 0.055 0.001††
Rue 28-hue
Number of errors 0.610 0.081 0.186
Tritan unspecific errors 0.714 0.074 0.01†
PDT (sheet)
Successful number of sheets 0.758 0.068 0.002††
†
𝑃 < 0.05, ††𝑃 < 0.01Mann-Whitney𝑈 test (aROC: area under the receiver
operating characteristic; AD: Alzheimer’s disease; cpds: cycles per degree;
PDT: perception digital test; SD: standard deviation).
Table 4: Pearson’s correlation between psychophysical tests and
Mini Mental State Examination.
Psychophysical test 𝑟 𝑃 value
Visual acuity 0.457 0.001††
Contrast sensitivity
3 cpds 0.366 0.011††
6 cpds 0.516 0.001††
12 cpds 0.451 0.001††
18 cpds 0.468 0.001††
Rue 28-hue
Number of errors −0.271 0.063
Tritan unspecific errors −0.329 0.023†
PDT
Successful number of sheets 0.536 0.001††
†
𝑃 < 0.05, ††𝑃 < 0.01 Pearson’s test (AD: Alzheimer’s disease; cpds: cycles
per degree; PDT: perception digital test).
perception. Thus, in MAD patients the spatial frequency
of 18 cpds showed the greatest decrease in CS (44.57%)
compared with the age-matched control group. The analysis
of the ROC curves (Table 3; Figure 2(b)) showed that, for
MAD patients, the highest spatial frequencies analyzed (18
and 12 cpds) had the widest areas under the ROC curves
for all the parameters analyzed. The 18-cpd frequency had
the strongest correlation, followed by the 12-cpd frequency.
A good correlation was detected also for the 6- and 3-cpd
frequencies (Table 3; Figure 2(b)).
A positive and statistically significant linear association
was found between CS for all spatial frequencies tested and
MMSE score (Table 4).
3.3. Color Perception. The analysis of color vision with
the Rue 28-hue test showed that there were no significant
differences in the color perception between patients with
MAD and age-matched control group based on the total
error score (Table 2). However, the analysis of the tritan axis
revealed that (i) the number of tritan unspecific errors was
significantly increased in MAD patients in comparison with
age-matched control (Table 2; Figure 1(c)), (ii) aROC curve
drawn for the total tritan unspecific errors was statistically
significant (Table 3; Figure 2(c)), and (iii) there was a negative
and statistically significant linear association between tritan
unspecific errors and the MMSE score (Table 4).
3.4. Perception Digital Test (PDT). The PDT mean value
found for the control group was significantly higher than
that of the MAD group. The analysis of the individual
sheets revealed a significant difference in sheets 2, 8, and 10
between MAD and age-matched control subjects (Table 2;
Figure 1(d)).
The aROC curve for PDT showed a statistically signifi-
cant wide area. However, when the analysis was calculated
by individual sheets, no significant differences were found
(Table 3; Figure 2(d)). A positive and statistically significant
linear association was found between the PDT and MMSE
score (Table 4).
4. Discussion
ADpatients reportedlymanifest subjective visual complaints,
including the inability to read, spatial deficits, or difficulty in
recognizing faces despite having relatively good visual acuity
values and visual fields. For this reason the patients in our
studywere carefully selected so that samplewas quite uniform
regarding VA and MMSE. In addition, between different SC
tests available, the CSV-1000 was chosen because results are
more independent with respect to the VA [37].
One of the relevant points of the present study concerns
MMSEvalue.OurMADpatientswere homogeneous in terms
of their disease stage and had a high MMSE mean value
(23.3 ± 3.1), higher than any value found in the literature
[36, 37, 49–51]. This means that all MAD patients included
in this study were in a very early stage of the disease.
4.1. Visual Acuity. VA values in the present study were within
normal limits for this age range. However, mean VA in MAD
patients was significantly decreased in comparison with age-
matched control subjects. VA values in AD patients have
been controversial.Thus, several studies reported no decrease
in VA in patients with Alzheimer’s neurodegeneration [36,
40, 41, 50, 52–54] while others showed a decrease in VA
[55] which in some instances was associated with visual
hallucinations [56].
4.2. Contrast Sensitivity. We found that, in comparison with
age-matched control subjects, CS in MAD patients was
significantly reduced in all spatial frequencies, the reduction
being more pronounced at higher frequencies. Specifically,
at a spatial frequency of 18 cpds, MAD patients showed
a 44.57% CS reduction in comparison with age-matched
control. High spatial frequencies are recorded in the P cells
of the retina, which are more concentrated in the macular
area. Low spatial frequencies are recorded by the M cells
located over the entire retina [57]. Our CS results suggest
that MAD patients undergo an impairment of both P- and
M-cell function, P cells being the most affected. This finding
6 Journal of Ophthalmology
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Figure 2: Areas under the ROC curves of the psychophysical tests in discriminating between mild AD patients and control subjects. (a)
Visual acuity (dec), (b) contrast sensitivity, (c) Rue 28-hue color test, and (d) perception digital test.
correlates with data recently published by our group [9] in
which patients with MAD had a significant decrease in the
nerve fiber layer thickness in themacular area comparedwith
age-matched controls. By contrast, the significant decrease
in CS for the lower spatial frequencies found here in MAD
patients did not parallel OCT findings in the peripapillary
region in the fact that the decrease in the nerve fiber layer
thickness reported by our group in this retinal region did
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not reach significance when compared with controls. These
findings tempt us to postulate that, in MAD, CS seems to
detect the M pathway impairment earlier than OCT does.
CS in AD has been analyzed for several years. Although
in two studies no differences between AD and age-matched
control were detected [40, 54], most reports found that CS
function is impaired in AD patients. In some instances, CS
was reduced at all spatial frequencies examined [34–36, 51, 53,
55, 58–60], while in others the greater decline corresponded
to high spatial frequencies [34, 51, 61] and in still others
the lower spatial frequencies were the most affected [49, 50,
52, 62]. Possible reasons for such discrepancies may lie in
differences among samples and the CS test used [37]. Thus,
the Regan chart, a low-contrast letter, and the Vistech VCTS
6500 are influenced by the VA value while the Pelli-Robson
test and the Freiburg test are independent of VA [37]. In the
present study, we use the CSV-1000 test which is based on
the Pelli-Robson test and it can thus be assumed that it is not
influenced by VA values.
In agreement withmost studies on CS in AD, CS function
was impaired in our cohort of early AD. However, the
degree of involvement varied among spatial frequencies, the
reduction being greater at the higher ones. Notably, in the
studies reported in which CS was equally decreased in all
spatial frequencies, AD patients were at a more advanced
stage of the disease than were ourMAD patients, as indicated
by their lower MMSE values. There are only two studies with
results consistent with ours, showing an increased decline
at the higher spatial frequencies. However, both studies
presented methodological differences with respect to ours.
In the Neargarder et al. study [37], the results could have
been influenced by the poorer VA of the patients, the test
selected, and the great variability of MMSE (6–26) in the
AD group. Meanwhile, the Gilmore et al. study [63] included
only the participants who provided a valid response across all
spatial frequencies, removing any patients who were not able
to discriminate all checked spatial frequencies. Given these
data, it seems that the 12- and 18-cpd spatial frequencies are
themost affected in the early stages on the disease and thus as
the disease progresses, all spatial frequencies become equally
involved. According to our ROC values, the most sensitive
spatial frequencies were 18 cpds (the highest), followed by the
12 cpds (85.7% and 83.2%, resp.); therefore, the highest spatial
frequencies appear to have the highest diagnostic value in
MAD neurodegeneration.
The fact that CS is impaired in ADpatients in comparison
with healthy elderly subjects has significant implications
for cognitive abilities and daily function of AD patients
[37], especially when the first spatial frequencies affected,
according to our data, appear to be those corresponding to
macular function.
4.3. Color Perception. When assessing color perception in our
MAD patients, we found no significant differences in terms
of color defects in comparison with age-matched control
subjects. However, we found that our MAD patients made
significantly more (72.62%) unspecific errors in the tritan
(blue) axis than did the controls, which represented almost
a threefold increase in the errors committed by the MAD
group.
Unlike subjects with a loss of color vision due to focal
cortical lesions, patients with AD rarely complain of color-
vision deficits. Color testing in patients with AD is con-
troversial because these patients have a deficit in naming
colors and thereforemight have trouble verbalizing the colors
or nominating numbers and shapes that are being viewed.
The color test used in the present study does not require
naming, although it should be taken into account that test
performance depends on the memory of the patients and
therefore, for appropriate testing, the instructions need to be
repeated by the examiner during test session, when necessary.
Some studies using the Farnsworth and Ishihara tests
have found no color perception differences between patients
with AD and the control group [58, 64, 65]. On the other
hand, several studies using the City University Color Test
found defects in the tritan axis and reported a correlation
with the degree of dementia [30, 50, 66]. These data are
consistent with the results reported by other authors using the
Ishihara test [55] and the City University Color Test [67, 68].
By contrast, Pache et al., using the Ishihara test and the PV-16,
found that unspecific errors not associated with a specific axis
were more prevalent in AD patients compared to controls;
however, this finding was not related to the severity of the
disease [31]. This discrepancy among color-vision results in
AD patients may be due to differences in the color test
applied, so that comparisons of the results are difficult to
interpret.
Salamone et al. postulated that the problem of color
discrimination in patients withAD is not purely cognitive but
seems to be related to damage in the structures responsible
for the perception of color stimuli [32]. This statement is
consistent with the evidence that extrastriate lesions may
result in tritanomalous color deficits [50] and that the
extrastriate cortex is severely affected in AD. The fact that
no tritanomaly was found in our MAD patients but an
increment of unspecific errors appeared along the tritan
axis leads us to postulate that, in addition to the general
loss of M cells and P cells that seems to be taking place
in our patients (as mentioned above), the K pathway may
also be involved, given that the blue-yellow spectrum is
associated with this pathway [69]. Bistratified ganglion cells
receive blue-on/yellow-off color-opponent excitation signals
from the short-wavelength sensitive S cones and project this
information to the koniocellular layers in the LGN [70].
4.4. Perception Digital Test (PDT). The MAD patients of
the present study made significantly more mistakes in PDT
answers than did the age-matched control subjects. Given
that no statistically significant differences in educational level
were found among groups, the influence of this variable could
be ruled out.
The part of the brain initially involved in AD is the tem-
poral cortex, which is then followed by the temporoparietal
association cortex [1, 71]. As a consequence, visual perception
disorders are frequently associated with Alzheimer’s neu-
rodegeneration [71]. Before PDT development [46] visuoper-
ceptual tests showed low sensitivity for detecting disorders in
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the early stages of the disease [72]. The development of more
sensitive neuropsychological tests such as PDT has enabled
the assessment of visual perception disorders in initial AD
[46]. In view of the good predictive value (aROC = 0.758, 𝑃 <
0.01) provided by the application of the PDT, we postulate
PDT as a useful ancillary screening test for MAD.
4.5. aROC. To the best of our knowledge, no predictive
(ROC) analysis is available for the diagnosis value of different
visual psychophysical test in AD. A noteworthy finding of the
present work was that the test with the greatest prognostic
value in MAD patients was CS for 18-cpd and 12-cpd spatial
frequencies (aROC 0.857 and 0.832, resp.), followed by VA
(aROC 0.771), PDT (aROC 0.758), and unspecific errors in
the blue region (aROC 0.714).
4.6. Pearson’s Correlation. As mentioned above, our AD
patients had a high mean MMSE value, the highest so far
reported to the best of our knowledge. However, given that
MMSE values ranged from 17 to 31, we investigated whether
the MMSE value influences the test outcome. As a result, we
found a significant correlation between MMSE values and
PDT (𝑟 = 0.536), followed by the CS for 6-cpd (𝑟 = 0.516)
and 18-cpd (𝑟 = 0.468) spatial frequencies, and VA (𝑟 =
0.457) and CS for 12-cpd (𝑟 = 0.451) and 3-cpd (𝑟 = 0.366)
spatial frequencies. A negative correlation was also found
between MMSE and the unspecific errors in the tritan region
(𝑟 = −0329). All these findings showed that as the disease
progresses, the answers to different tests used for assessing
visual skills worsened.
Possible drawbacks of the study include the cross-
sectional design, the subjective nature of the psychophysical
testing (which depends on cognitive abilities), and the early
stage of disease (mild cognitive impairment, which can be
due to reasons other than AD). Another limitation could be
the sample size. Gathering large samples is a difficult task
when dealing with MAD patients. This was especially true
in the present study in which the inclusion criteria were
very demanding in order to recruit patients in early stages
of AD who were also free of ocular pathology, the latter
requisite limiting patient enrollment given the age range of
the sample. Nevertheless, our sample size was comparable to
that reported in the literature [36, 37, 40, 50, 51, 59].
5. Conclusions
In conclusion, our study demonstrates a deficit in visual per-
ception in early stages of AD,manifested by reductions inVA,
CS, and color discrimination. These psychophysical changes
correlate with retinal morphological changes (decreased
RNFL macular thickness as detected by OCT) detected in
the same group of patients [9]. Furthermore, the observed
changes in PDT suggest a visual integration deficit, possibly
due to, at least in part, an incipient cortical dysfunction.
The study of the predictive value of the tests analyzed herein
showed that, in the most incipient AD grades, tests having
the greatest predictive value are the CS, VA, unspecific errors
in tritan region, and the PDT. The fact that no differences
were detected between our MAD patients and age-matched
control subjects in the dilated fundus examination highlights
the importance of applying psychophysical tests in patients
withMAD. Given the difficulty in gathering larger samples in
AD, broader transverse as well as longitudinal studies would
be useful to track changes in the psychophysical tests as the
disease progresses.
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